Skip to content

Metabolic & GLP-1 · Reference monograph

Synthetic amylin analogue for type 1 and type 2 diabetes

Reference compound — not available from Purity Peptides. Shown for research context.

Overview

Pramlintide is a synthetic analogue of human amylin designed to overcome the native hormone's tendency to aggregate. Researchers at Amylin Pharmaceuticals replaced the residues at positions 25, 28 and 29 with prolines, the residues found at those positions in rat amylin, producing a soluble, non-amyloidogenic peptide that retains amylin receptor activity.

Pramlintide was approved by the US FDA in 2005 as an adjunct to mealtime insulin in type 1 and type 2 diabetes, becoming the first amylin-based medicine. Its label carries a prominent warning about the risk of severe hypoglycaemia when used alongside insulin. A European marketing application was withdrawn, and global availability is limited. In research, pramlintide serves as a stable tool for amylin receptor pharmacology, satiety studies and investigations of postprandial glucagon and gastric emptying. It also helped establish proof of concept for amylin-based approaches, contributing to current exploration of long-acting amylin analogues and amylin-GLP-1 combinations in obesity research. Pramlintide is supplied here only as a reference material for laboratory work.

Mechanism studied

  1. Pramlintide
  2. Amylin receptors
  3. Gastric emptying & glucagon ↓
  4. Postprandial glucose

Pramlintide mimics amylin at AMY receptors, which comprise the calcitonin receptor in complex with receptor activity-modifying proteins. Activation increases cAMP signalling, particularly in the area postrema and connected brainstem circuits. These central actions slow gastric emptying, suppress inappropriate postprandial glucagon secretion and enhance satiety, together reducing the rise in glucose after meals. Unlike GLP-1 receptor agonists, pramlintide does not directly stimulate insulin secretion. Because its mechanism complements insulin rather than replacing it, research often examines pramlintide alongside insulin to model the combined endocrine output of healthy beta cells. Its short half-life produces transient receptor engagement.

Research highlights

  • 01Designed by proline substitution at positions 25, 28 and 29, borrowing from the non-aggregating rat amylin sequence.
  • 02Approved by the FDA in 2005; the European marketing application was withdrawn.
  • 03Provided the first clinical validation that amylin receptor agonism influences postprandial glucose and satiety.
  • 04Rodent and early human studies combining pramlintide with metreleptin explored amylin-leptin synergy.
  • 05Open questions include how amylin and calcitonin receptor selectivity affect the profile of next-generation analogues.

Latest published research

451 papers on PubMed →

  1. Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?

    Muskiet MHA et al. · Lancet (London, England) · 2026 Dec 20 · PMID 41207308

  2. Plasma amylin levels in migraine and after erenumab treatment: A REFORM study

    Domínguez-Moreno R et al. · Headache · 2026 Oct 13 · PMID 42867283

  3. Oral and Injectable (Non-Insulin) Pharmacological Agents for the Treatment of Type 2 Diabetes

    Feingold KR et al. · · 2000 · PMID 25905364

  4. Adjunctive Treatments for Patients with Type 1 Diabetes Using Automated Insulin Delivery Systems. A Narrative Review

    Kitsios K et al. · Diabetes technology & therapeutics · 2026 Sep 4 · PMID 42695140

  5. Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials

    Alhazmi A et al. · Diabetes, obesity & metabolism · 2026 Sep · PMID 42452898

  6. Metal-tuned antimicrobial peptides and zincophore pathways: from coordination chemistry to targeted therapeutics

    Garstka-Litwin K et al. · Journal of inorganic biochemistry · 2026 Jul · PMID 41850952

  7. In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive doping research

    Alhalabi H et al. · Journal of pharmaceutical and biomedical analysis · 2026 Jun 15 · PMID 41702251

  8. Pramlintide

    · 2006 · PMID 30000033

Live feed from PubMed (NCBI) for “Pramlintide”, updated 2026-10-30. Listing a paper is not an endorsement of its findings.

Registered studies

64 on ClinicalTrials.gov →

From the public ClinicalTrials.gov registry for “Pramlintide”, updated 2026-10-30. Shown for research context only; Purity Peptides products are not for human use.

Key references

  1. [1]Symlin® prescribing information — FDA
  2. [2]Ratner et al., 2004 — Diabet Med

FAQ

  • Pramlintide differs at three positions, where proline residues replace the native amino acids. These substitutions disrupt the beta-sheet formation responsible for amyloid fibrils, making the peptide soluble and stable in solution while preserving its ability to activate amylin receptors.

  • Pramlintide is an approved prescription medicine in the United States as an adjunct to mealtime insulin in type 1 and type 2 diabetes. Its European marketing application was withdrawn, and it is not widely available in other regions.

  • Pramlintide demonstrated that amylin receptor agonism influences food intake in clinical research and rodent models. That observation led to research into longer-acting amylin analogues and dual amylin and calcitonin receptor agonists, now being evaluated alongside GLP-1-based approaches.

FOR RESEARCH USE ONLY.Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.

Related compounds

WhatsApp